Cellular Biomedicine Group (NSDQ: CBMG), a China-US cell therapy company, acquired CAR-T cancer immunotherapy technology from the Chinese PLA General Hospital (the 301 hospital) of Beijing (see story). The two groups will form a partnership for further development of the products in China. The PLA Hospital has already conducted early clinical trials of the technology on CD19-positive acute lymphoblastic leukemia, CD20-positive lymphoma, CD30-positive Hodgkin’s lymphoma and EGFR-HER1-positive advanced lung cancer.
Help employers find you! Check out all the jobs and post your resume.
